A PHASE 1B, MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY TO DETERMINE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF DNL201 IN SUBJECTS WITH PARKINSON'S DISEASE

This Study is
No Longer Enrolling

Details
Age

Adult

Phase

I - Research Studies that focus on the safety of a drug. The goal is to determine the drug's most frequent and serious adverse events and, often, how the drug is broken down and excreted by the body. These studies usually involve a small number of participants.

Type of Study

Treatment

Locations

University of Colorado Hospital

Study ID

Protocol Number: 18-2423

More information available at ClinicalTrials.gov: NCT03710707

Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers